A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-02-26) →
What happened
Korea United Pharm reported separate results for FY2025: revenue of US$201M (0% year on year), operating profit of US$34.4M (−11.9% year on year) and net income of US$43.4M (+92.4% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$201M |
|---|---|
| Revenue vs a year earlier | 0% |
| Operating profit | US$34.4M |
| Net income | US$43.4M |
| Period | FY2025 (separate) |
| Filed | 2026-02-19, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260219800973 → open original filing |
Versions of this filing
- 2026-02-19Original (this page)
- 2026-02-26Amendment 1
Source: DART. Information only, not investment advice.